SHANGHAI, SHIINAHA iyo CAMBRIDGE, MASSACHUSETTS, US, Oktoobar 27, 2022 - JW Therapeutics (HKEX: 2126), oo ah shirkad madax-bannaan oo tignoolajiyada cusub leh oo diiradda saaraysa horumarinta, soo saarista, iyo ka-ganacsiga alaabada difaaca unugyada, iyo 2 Bio (NASDAQ: TSVT), oo ah hormuudka shirkadda daawaynta unugyada immuno-oncology, ayaa maanta ku dhawaaqday isbahaysi istaraatiijiyadeed si loo dhiso madal horumarinta daawaynta unugyada tarjumaadda iyo kiliinikada loogu talagalay in si dhakhso leh loo sahamiyo. Immunotherapy ku salaysan unug wax soo saarka ee dhul weynaha Shiinaha, Hong Kong (Shiinaha), iyo Macao (Shiinaha).
The initial focus of the collaboration is 2seventy’s MAGE-A4 TCR program in solid tumors, which is being developed as part of a collaboration with Regeneron. MAGE-A4 is a member of the MAGE family of cancer-testis antigens expressed in a number of solid tumor types. The program is designed to develop Daawaynta T-cell reseptor (TCR). loogu talagalay daaweynta MAGE-A4 burooyinka adag ee togan.
Waxaa laga yaabaa inaad jeceshahay inaad akhriso: CAR T-Cell daaweynta Shiinaha
“We are delighted to work with 2Seventy bio to jointly develop the MAGE-A4 TCR program and potentially other assets in China,” said Dr. Mark J. Gilbert, Chief Medical Officer of JW Therapeutics. “2Seventy is a top-tier cell therapy company with advanced technologies and a highly experienced team. This alliance will further leverage our world-class integrated capabilities, including translational research and clinical development, and we look forward to accelerating the development of more cell immunotherapy products with breakthrough therapeutic value to serve more patients with cancer in China and potentially worldwide.”
“The true patient benefit of this collaboration lies in the ability to establish additional capabilities to rapidly test, learn, and progress our innovative cell therapy programs,” said Steve Bernstein, chief medical officer, 2Seventy bio. “JW Therapeutics possesses extensive understanding of the unmet medical needs of the population and the regulatory affairs process in China, as well as the clinical development pathways. The opportunity to bring together our distinctive areas of experience to create a differentiated platform supports our goal of bringing new therapies to patients as quickly as possible.”
Waxaa laga yaabaa inaad jeceshahay inaad akhriso: CAR T-Cell therapy Qiimaha ee Shiinaha
Sida ku cad shuruudaha heshiiska, 2 waxay siin doontaa JW Therapeutics shatiga daaweynta unugyada MAGE-A4 ee dhul weynaha Shiinaha, Hong Kong (Shiinaha), iyo Macao (Shiinaha). JW Therapeutics ayaa mas'uul ka noqon doonta horumarinta, wax soo saarka, iyo ganacsiga gudaha Shiinaha. 2 ayaa u qalma in ay helaan horumarro iyo royalties dakhliyada alaabta ee Shiinaha. Intaa waxaa dheer, 2 ayaa laga yaabaa inay ka faa'iidaystaan xogta hore ee kiliinikada ee laga soo saaray iskaashiga si ay u taageeraan horumarinta juqraafiyada kale. Xiritaanka wax kala iibsigu waxa ay ku xidhnaan doontaa oggolaanshaha saamilayda JW Therapeutics iyo shuruudaha xidhitaanka dhaqameed ee kale.
Ku saabsan barnaamijka MAGE-A4
MAGE-A4 waa xubin ka mid ah qoyska MAGE ee kansarka-testis antigens oo lagu muujiyey tiro ka mid ah noocyada burooyinka adag. Barnaamijkayagu waxa uu shaqaalaysiiyaa TCR aad u awood badan oo laga helay iskaashigayada MediGene
taas oo aqoonsata HLA-soo bandhigtay MAGE-A4 peptides oo sii wanaajisay awoodda unugyadan dib loo hagayo T-yada iyadoo la adeegsanayo tignoolajiyada soo-dhowaynta ee CTBR12 TGF-beta “flip”, taas oo u beddeleysa saamaynta difaaca jirka ee TGF-beta oo ah calaamad firfircoon oo unugyada T ah. . Regeneron iyo 2seventy bio ayaa si wadajir ah u horumarinaya barnaamijka iyaga oo la galay 2018.
Waxaa laga yaabaa inaad jeceshahay inaad akhriso: CAR T-Cell therapy for multiple myeloma gudaha Shiinaha
Ku saabsan Daaweynta JW
JW Therapeutics (HKEX: 2126) waa shirkad madax-banaan oo hal-abuur leh bayotechnoolajiyada diiradda saara horumarinta, soo saarista, iyo ganacsiyeynta alaabada difaaca unugyada, waxaana ka go'an inay noqoto hogaamiye hal-abuurnimo ee immunotherapy unug. Waxaa la aasaasay 2016, JW Therapeutics waxay dhistay madal heer caalami ah oo loogu talagalay horumarinta alaabada ee unugyada difaaca jirka, iyo sidoo kale dhuumaha alaabada oo daboolaya labadaba malignanciyada dhiigga iyo burooyinka adag. JW Therapeutics waxaa ka go'an in ay keento horumar iyo tayada unugyada difaaca jirka iyo rajada daawaynta bukaanka Shiinaha iyo adduunka oo dhan, iyo hogaaminta horumarka caafimaadka iyo heerka caadiga ah ee Daaweynta difaaca unugyada Shiinaha warshadaha.
Ilaa 2 bio
Magacayaga, 2 bio, ayaa ka tarjumaysa sababta aan u samayno waxa aan samayno - WAQTIGA. Kansarku wakhtiga wuu dilaacaa, hadafkayaguna waa inaan ku shaqayno xawaaraha ugu badan ee fikirka bini'aadamka loogu turjumayo ficil-270 mayl saacaddiiba-si loo siiyo dadka aanu u adeegno wakhti badan. Waxaan dhisaynaa shirkadda hormuudka u ah daawaynta unugyada difaaca jirka, oo diiradda saareysa daahfurka iyo horumarinta daawayn cusub oo run ahaantii carqaladeeya muuqaalka daaweynta kansarka.
Iyada oo si qoto dheer loo fahmo jawaabta difaaca jidhka bini'aadamka ee unugyada burooyinka iyo sida loogu turjumo daaweynta unugyada ficil ahaan, waxaan u adeegsaneynaa aqoontan si aan u bixinno jiilka soo socda daaweynta unugyada kuwaas oo diiradda saaraya noocyo badan oo ah malignancies hematologic, oo ay ku jiraan FDA-ansixisay ee ugu horeysay. Daawaynta unugyada CAR T ee myeloma badan, iyo sidoo kale burooyin adag. Cilmi-baaristayada iyo horumarintayadu waxay diiradda saarayaan bixinta daawaynta loogu talagalay ujeeddada "fekerka" ka xariifsan oo ka dhaqso badan cudurka. Muhiimad ahaan, waxaan diirada saareynaa gaarista yoolalkaan anagoo si dhab ah u ilaalinayna "sababteena" oo aan ilaalino dadkeena iyo dhaqankeena maskaxda ugu sareysa maalin kasta.
Odhaahyada Horu-socodka ah ee Daaweynta JW
The forward-looking statements are based on the management’s expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described. Significant risks and uncertainties, include those discussed below and more fully described in Hong Kong Exchanges and Clearing Limited (HKEX) reports filed by the company. Unless otherwise noted, the company is providing this information as of the date it publicized, and expressly disclaims any duty to update the information contained in the issues and relevant information, or provide any explanation.
Waxaa laga yaabaa inaad jeceshahay inaad akhriso: FUCASO loogu talagalay daawaynta myeloma badan
Ogeysiis Digniin ah oo ku Saabsan Bayaanada Hor-u-fiirinta ee 2 bio
Siideyntani waxa ay ka kooban tahay "odhaaho hore u socda" oo ku dhex jira macnaha Sharciga Dib-u-habaynta Dammaanad-qaadka Dammaanadda Gaarka ah ee 1995. Odhaahyadan waxa ku jira, laakiin aan ku xaddidnayn: bayaannada ku saabsan qorshayaashayada, xeeladaha, wakhtiyada iyo waxyaabaha laga filayo marka la eego horumarka, soo saarista ama iibinta musharixiinta alaabtayada, oo ay ku jiraan natiijooyinka iyo wakhtiga la filayo ee tijaabooyinka caafimaad ee socda iyo kuwa la qorsheeyay ee musharaxiintayada alaabada ee Shiinaha iyo xawaaraha aan ku keeni karno musharaxiintaas tijaabada caafimaadka; statements about the efficacy and perceived therapeutic benefits of our product candidates and the potential indications, market opportunities and demand therefor; statements about the strategic plans for 2seventy bio and potential corporate development opportunities; statements regarding the company’s financial condition, and other future financial results; and statements about our ability to execute our strategic priorities.
Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation; the risk that our plans with respect to the preclinical and clinical development and regulatory approval of our product candidates may not be successfully achieved on the planned timeline, or at all.
For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2021, as supplemented and/or modified by our most recent Quarterly Report on Form 10-Q and any other filings that we have made or will make with the Securities and Exchange Commission in the future.
All information in this press release is as of the date of the release, and 2seventy bio undertakes no duty to update this information unless required by law.
